Showing results (11-20 of 25) with videos related to
Sort By:
Pageof 3
British Journal of Haematology|May 10, 2017
Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 studyLuca Ceriani, Maurizio Martelli, Annarita Conconi, et al.Cancer|July 7, 2011
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced diseaseAlessandra Tedeschi, Giulia Benevolo, Marzia Varettoni, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2006
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphomaSandra J Strauss, Frank Morschhauser, Juergen Rech, et al.British Journal of Haematology|July 22, 2015
The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphomaEnrica Marchi, Kelly M Zullo, Jennifer E Amengual, et al.Ejhaem|February 23, 2023
Real-world clinical effectiveness and safety of CT-P10 in patients with diffuse large B-cell lymphoma: An observational study in EuropeMark J Bishton, Gilles Salles, Camille Golfier, et al.The New England Journal of Medicine|May 12, 2021
Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell LeukemiaEnrico Tiacci, Luca De Carolis, Edoardo Simonetti, et al.Hemasphere|August 7, 2024
The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 studyAndrew D Zelenetz, Wojciech Jurczak, Vincent Ribrag, et al.Nature Medicine|January 17, 2024
Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphomaFrederick L Locke, Simone Filosto, Justin Chou, et al.Blood Cancer Discovery|July 2, 2024
A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell LymphomasFederico Stella, Annalisa Chiappella, Beatrice Casadei, et al.Blood|October 23, 2023
Epidemiology and geographic clustering of Erdheim-Chester disease in Italy and FranceFrancesco Peyronel, Julien Haroche, Corrado Campochiaro, et al.Pageof 3